Lead Product(s) : BX004
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Laidlaw & Company
Deal Size : $12.0 million
Deal Type : Private Placement
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million
Details : The Company intends to use the proceeds to support the completion of the Phase 2b of BX004, BiomX’s fixed phage cocktail, for the treatment of people with CF with chronic pulmonary infections.
Product Name : BX004
Product Type : Microorganism
Upfront Cash : Undisclosed
February 26, 2025
Lead Product(s) : BX004
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Laidlaw & Company
Deal Size : $12.0 million
Deal Type : Private Placement
Lead Product(s) : BX004
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Deerfield Management Company
Deal Size : $50.0 million
Deal Type : Private Placement
BiomX Enters Merger Agreement with Adaptive Phage Therapeutics and $50 Million Financing
Details : The proceeds will fund Phase 2b for BX004 in chronic pulmonary infections in CF patients and Phase 2 results from APT’s clinical-stage BX211, for the treatment of S. aureus infections.
Product Name : BX004
Product Type : Microorganism
Upfront Cash : Undisclosed
June 03, 2024
Lead Product(s) : BX004
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Deerfield Management Company
Deal Size : $50.0 million
Deal Type : Private Placement
Lead Product(s) : BX004
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Deerfield Management Company
Deal Size : $50.0 million
Deal Type : Private Placement
BiomX Announces Acquisition Of Adaptive Phage Therapeutics and $50 Million Financing
Details : Proceeds fund BX004 for chronic pulmonary infections in CF patients and BX211 for S. aureus in Phase 2.
Product Name : BX004
Product Type : Microorganism
Upfront Cash : Undisclosed
March 18, 2024
Lead Product(s) : BX004
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Deerfield Management Company
Deal Size : $50.0 million
Deal Type : Private Placement
Lead Product(s) : SPL84
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SPL84, has shown to have completely restored CFTR activity in the CF gold standard pharmacological model, suggesting potential cure for these patients.
Product Name : SPL84
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
December 14, 2022
Lead Product(s) : SPL84
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BX004
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In vitro results demonstrate that BiomX’s phage cocktail, BX004, was able to penetrate biofilm and was efficacious in significantly reducing bacterial levels of Pseudomonas aeruginosa encased in biofilm, relative to two different antibiotics.
Product Name : BX004
Product Type : Microorganism
Upfront Cash : Inapplicable
September 06, 2021
Lead Product(s) : BX004
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable